Deflazacort (Emflaza)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • Treatment of patients at least 5 years of age with Duchenne muscular dystrophy (DMD)

Patients must meet the following criteria for the indication(s) above:

  • Diagnosis of Duchenne muscular dystrophy
  • 5 years of age of older
  • Has tried prednisone but experience severe adverse events (i.e., Cushingoid appearance, obesity, behavioral abnormalities/psychiatric adverse events) that could not be managed

Dosing:

  • Approximately 0.9mg/kg/day once daily (round up to nearest possible dose when using tablets, or round up to nearest tenth of a mL when using suspension)
  • Concomitant moderate of strong CYP3A4 inhibitors (e.g., clarithromycin, fluconazole, diltiazem, verapamil): reduce dose to 1/3 of usual dose
  • Avoid use with moderate or strong CYP3A4 inducers

Approval:

  • 1 year

Last review date: May 1, 2017